Jonathan Slonin - May 23, 2022 Form 4 Insider Report for Pacira BioSciences, Inc. (PCRX)

Role
Chief Clinical Officer
Signature
/s/ Kristen Williams, Attorney-in-Fact
Stock symbol
PCRX
Transactions as of
May 23, 2022
Transactions value $
$104,740
Form type
4
Date filed
5/25/2022, 04:16 PM
Previous filing
Aug 5, 2021
Next filing
Jun 8, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PCRX Common Stock Options Exercise $105K +2K +7.53% $52.37 28.6K May 23, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PCRX Stock Option (Right to Buy) Options Exercise $0 -2K -5.33% $0.00 35.5K May 23, 2022 Common Stock 2K $52.37 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 209 shares of common stock acquired under the issuer's employee stock purchase plan in December 2021.
F2 The stock option vested and became exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date.